Atossa Therapeutics, Inc. insider trading

Every open-market purchase and sale by Atossa Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Atossa Therapeutics, Inc.’s insiders pay?

From January 9, 2013 to April 11, 2024, 5 insiders reported 6 open-market purchases and 2 sales not made under a pre-set plan in Atossa Therapeutics, Inc. After sales, the shares moved −72.0% against the index over 12 months (a negative figure means selling was the right call).

Atossa Therapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Weaver Gregory L	Former EVP, CFO, & Director	2	—	—	2	−72.0% (1)	November 17, 2023
Chen Shu-Chih	Director	1	—	—	0	—	January 21, 2016
Finn Jonathan	Director	1	—	—	0	—	April 11, 2024
Quay Steven C	President & CEO	1	—	—	0	—	January 21, 2016
Remmel H. Lawrence	Director	1	—	—	0	—	January 9, 2013

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Atossa Therapeutics, Inc. · Funds · Politicians